(Q36394987)

13 August 2017

1 reference

title

Therapy of cancer by cytokines mediated by gene therapy approach (English)

1 reference

13 August 2017

0 references

Cheng Qian

1

1 reference

13 August 2017

Xin Yuan Liu

series ordinal

2

1 reference

13 August 2017

Jesus Prieto

series ordinal

3

1 reference

13 August 2017

publication date

1 February 2006

1 reference

13 August 2017

number of pages

7

1 reference

inferred from page(s)

published in

Cell Research

1 reference

13 August 2017

volume

16

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

182-188

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cr.7310025

13 August 2017

exact match

0 references

cites work

IL-12 gene therapy for cancer: in synergy with other immunotherapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

New strategies to enhance gene therapy efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Biologic therapy of liver tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Gene therapy of a rat follicular thyroid carcinoma model with adenoviral vectors transducing murine interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Anti-tumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Alpha(v)beta(3) integrin-mediated adenoviral transfer of interleukin-12 at the periphery of hepatic colon cancer metastases induces VCAM-1 expression and T-cell recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Cancer gene therapy: fringe or cutting edge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Gene therapy: designer promoters for tumour targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Cytokine gene transfer into dendritic cells for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

The Semliki Forest virus vector induces p53-independent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Enhancing immune responses using suicidal DNA vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

An oncolytic adenovirus controlled by a modified telomerase promoter is attenuated in telomerase-negative cells, but shows reduced activity in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Gene therapy of liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Regulated gene expression systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Transcriptional activation by tetracyclines in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Adenovirus-mediated inducible gene expression in vivo by a hybrid ecdysone receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Adenovirus-mediated regulable target gene expression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

Immune response against tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

7 January 2021

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

7 January 2021

Interleukin-12: a cytokine at the interface of inflammation and immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

7 January 2021

Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

7 January 2021

Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

7 January 2021

A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

7 January 2021

Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310025

7 January 2021

Identifiers

DOI

10.1038/SJ.CR.7310025

1 reference

13 August 2017

1 reference